International Journal of Radiation Oncology*Biology*Physics
Clinical investigation: prostateLate morbidity profiles in prostate cancer patients treated to 79–84 Gy by a simple four-field coplanar beam arrangement
Introduction
Results from multiple series of patients with prostate cancer have demonstrated improvements in biochemical control when radiation doses between 76 and 82 Gy are delivered compared with conventional doses <70 Gy. This benefit is most evident for patients with intermediate- and high-risk feature 1, 2, 3, 4, 5. With standard conventional techniques, it has been evident that with the increase in dose, normal tissue toxicity increases. The Patterns of Care Studies suggest that severe complication rates double when conventional techniques are used to treat at doses >70 Gy (6). The goal of delivering higher doses to tumor while minimizing the dose to normal tissue has been the driving force behind the development of three-dimensional conformal radiotherapy (3D-CRT). Additional strategies used in conjunction with conformal techniques to better localize the target while restricting the dose to adjacent normal tissues have used daily ultrasonography, fiducial markers, and daily CT scanning for improved organ localization (7). Although these later advances are vital to the future of radiation oncology, they are not yet widely available in the general community. To improve the treatment of patients receiving their care in the 1500 facilities across the United States, it is important to develop treatment techniques that can be used in the general radiation community. It is important that such a technique meet certain requirements: (1) sufficient dose delivery, (2) demonstrated cure rates, (3) tolerable side-effect profile, (4) easy implementation with standard treatment equipment, and (5) quality assurance with standard port films. This communication presents a 3D conformal treatment technique developed in 1989–1992 that we believe fits these criteria.
Section snippets
Methods and materials
A review of our prospectively maintained prostate cancer data base revealed 156 patients treated for prostate cancer with a four-field, 3D conformal technique to 79–84 Gy between January 1, 1992 and February 28, 1999. Patients treated during this period with more complex beam arrangements such as noncoplanar techniques were excluded. All patients were believed to be at increased risk of failure because of the presence of at least one of the following presenting characteristics: T2b-T3 tumor,
GI complications
The median follow-up was 26 months for the cohort of interest and 86 months for the comparison group. The 5-year actuarial rate of Grade 2 GI complications was 9% in patients treated with lateral rectal shielding and 38% in patients treated without rectal blocking (p = 0.0004; Fig. 4). Late Grade 2 GI complications consisted primarily of rectal bleeding. Of the 132 patients treated with rectal blocking, 10 experienced late Grade 2 GI complications; 9 experienced rectal bleeding and 1 bowel
Discussion
This communication reports our observations on late GI and GU morbidity in patients with prostate cancer treated with 3D-CRT. We demonstrate that a dose that has been previously described to be associated with higher biochemical control rates can be safely delivered to the prostate with a four-field technique. A late Grade 2 GI morbidity rate of 9%, late Grade 2 GU morbidity rate of 12%, and a late Grade 3 GU morbidity rate of 2% were found. This is comparable to the morbidity rates for 3D-CRT
Conclusion
The treatment method described is a simple four-field conformal technique that can be easily implemented in the general radiation community. A dose of 79–84 Gy can be safely delivered to the prostate, with a 9% rate of late Grade 2 GI, 12% rate of late Grade 2 GU, and 2% rate of late Grade 3 GU complications.
References (15)
- et al.
Dose selection for prostate cancer patients based on dose comparison and dose response studies
Int J Radiat Oncol Biol Phys
(2000) - et al.
High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer
J Urol
(2001) - et al.
Defining the appropriate radiation dose for pretreatment PSA <10 ng/ml prostate cancer
Int J Radiat Oncol Biol Phys
(2000) - et al.
Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason ≤6, and pretreatment prostate-specific antigen ≤10)
Int J Radiat Oncol Biol Phys
(2001) - et al.
Patterns of Care StudiesPast, present, and future
Semin Radiat Oncol
(1997) - et al.
A Comparison of daily CT localization to a daily ultrasound-based system in prostate cancer
Int J Radiat Oncol Biol Phys
(1999) - et al.
Chronic rectal bleeding after high dose conformal treatment of prostate cancer warrants modification of existing morbidity scales
Int J Radiat Oncol Biol Phys
(1997)
Cited by (56)
Prostate Cancer
2015, Clinical Radiation OncologyDo intermediate radiation doses contribute to late rectal toxicity? An analysis of data from Radiation Therapy Oncology Group Protocol 94-06
2012, International Journal of Radiation Oncology Biology PhysicsLater outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer
2012, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :The treatment characteristics are summarized in Table 2. The standard fractionation group was treated 5 d/wk, using a conformal box technique, in 2 Gy fractions, to a total dose in the first segment at the International Commission on Radiation Units and Measurements point of 66–70 Gy, with minor modifications to the technique (5). An additional 10 Gy was administered through four oblique coplanar fields, with a 5-mm reduction to the posterior border of PTV2.
Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: An exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity
2012, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Patients treated with 3D-CRT to 78 Gy at 2 Gy per fraction in RTOG 9406 had a Grade 3 GI toxicity of 9% (31). Several others have sought to define normal tissue dose constraints based on retrospective analyses of toxicity and DVH data (5–8, 12–18), but only one other study involved patients treated with IMRT (16). Given the widespread use of IMRT and lack of DVH recommendations based on patients treated with IMRT, our study goals have importance.
Prostate Cancer
2011, Clinical Radiation Oncology: Third Edition